Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss
- Conditions
- Interventions
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 186
- Registration Number
- NCT03305263
- Locations
- 🇩🇰
Rigshospitalet, København, Denmark
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 9
- Registration Number
- NCT03283566
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Elena Gonzalez Brant, MD
- Target Recruit Count
- 17
- Registration Number
- NCT03275870
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03229746
- Locations
- 🇪🇬
Assiut university hospital, Assiut, Egypt
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT03215264
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Hydroxychloroquine for Prevention of Recurrent Miscarriage.
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 300
- Registration Number
- NCT03165136
- Locations
- 🇫🇷
Hôpital Bichat, Paris, France
🇫🇷CHU Estaing, Clermont-Ferrand, France
🇫🇷Hopital Saint Antoine, Paris, France
Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 37
- Registration Number
- NCT03085940
- Locations
- 🇮🇩
Ciptomangunkusumo Hospital, Jakarta, Indonesia
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 13
- Registration Number
- NCT03081702
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 54
- Registration Number
- NCT03032406
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Anti-Malarials in Incomplete Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 187
- Registration Number
- NCT03030118
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.